All Clinical Trials in Canada

A listing of 3904 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

Canada

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Spatial Memory Training and Cognitive Function

NCT07002996

Recruiting

Mild cognitive impairment (MCI) is often considered a transitional stage between normal aging and dementia, particularly Alzheimer's disease (AD). Patients with MCI have subjective memory complaints corroborated by standard neuropsychological tests but remain functionally autonomous. One of the first brain regions to show AD pathology is the hippocampus (HPC). Reduction in HPC volume is a strong predictor of AD dementia. Therefore, improvement or restoration of HPC structure and function is thus... Read More

Gender:

ALL

Ages:

55 years and above

Trial Updated:

07/18/2025

Locations: Douglas Mental Health University Institute, Verdun, Quebec

Conditions: Mild Cognitive Impairment

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Recruiting

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/18/2025

Locations: Bass Medical Group ( Site 0166), Walnut Creek, California +108 locations

Bass Medical Group ( Site 0166), Walnut Creek, California

Innovative Clinical Research Institute ( Site 0122), Whittier, California

Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton, Florida

Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood, Kentucky

University of Kentucky Chandler Medical Center ( Site 0158), Lexington, Kentucky

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133), Louisville, Kentucky

Louisiana State University Health Sciences Center New Orleans ( Site 0134), New Orleans, Louisiana

University of Maryland ( Site 0123), Baltimore, Maryland

Dana-Farber Cancer Institute-Lymphoma ( Site 0111), Boston, Massachusetts

University of Massachusetts Medical School ( Site 0119), Worcester, Massachusetts

St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings, Montana

Atlantic Health System ( Site 0116), Morristown, New Jersey

New York Medical College ( Site 0113), Valhalla, New York

Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156), Nashville, Tennessee

Hospital Italiano de Buenos Aires ( Site 2203), Ciudad Autonoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205), Mar del Plata., Buenos Aires

Hospital Aleman ( Site 2200), Buenos Aites, Caba

Instituto Alexander Fleming ( Site 2201), Caba, Not set

Hospital Privado Universitario de Córdoba ( Site 2202), Cordoba, Not set

Townsville University Hospital ( Site 1800), Douglas, Queensland

Grampians Health ( Site 1802), Ballarat, Victoria

Royal Perth Hospital-Haematology ( Site 1801), Perth, Western Australia

Hospital Erasto Gaertner ( Site 2302), Curitiba, Parana

Liga Norte Riograndense Contra o Câncer ( Site 2305), Natal, Rio Grande Do Norte

Hospital Paulistano ( Site 2300), Sao Paulo, Not set

Pesquisa Clínica do Serviço de Hematologia do Hospital das Clínicas da FMUSP ( Site 2306), Sao Paulo, Not set

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Biocenter ( Site 2401), Concepcion., Biobio

IC La Serena Research ( Site 2405), La Serena, Coquimbo

Oncocentro Valdivia ( Site 2407), Valdivia., Los Rios

FALP-UIDO ( Site 2400), Santiago., Region M. De Santiago

Clínica Inmunocel ( Site 2404), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 2409), Santiago, Region M. De Santiago

Bradfordhill ( Site 2403), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 3000), Beijing, Beijing

Chongqing University Cancer Hospital-Medical Oncology ( Site 3025), Chongqing, Chongqing

Chongqing University Three Gorges Hospital ( Site 3026), Chongqing, Chongqing

Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001), Guangzhou, Guangdong

Zhujiang Hospital ( Site 3002), Guangzhou, Guangdong

The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang, Henan

Henan Cancer Hospital-hematology department ( Site 3013), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017), Wuhan, Hubei

The First Affiliated Hospital of Nanchang University ( Site 3004), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 3005), Nanchang, Jiangxi

The First Hospital of Jilin University-Hematology ( Site 3012), Changchun, Jilin

Fudan University Shanghai Cancer Center ( Site 3009), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016), Cheng Du, Sichuan

Sichuan Cancer hospital-Oncology ( Site 3021), Chengdu, Sichuan

Zhejiang Cancer Hospital ( Site 3014), Hangzhou, Zhejiang

The First Affiliated Hospital Zhejiang University School of Medicine ( Site 3027), Hangzhou, Zhejiang

Hospital Pablo Tobon Uribe ( Site 0804), Medellin, Antioquia

Instituto Médico de Alta Tecnologia S.A.S ( Site 0803), Monteria, Cordoba

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0801), Bogota, Distrito Capital De Bogota

Oncologos del Occidente ( Site 0800), Pereira., Risaralda

Fundacion Valle del Lili ( Site 0802), Cali, Valle Del Cauca

Hospital Metropolitano - Sede Lindora ( Site 2500), Santa Ana, San Jose

CIMCA ( Site 2501), San Jose, Not set

centre hospitalier lyon sud-Service Hématologie ( Site 0702), Pierre-Bénite, Rhone

Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700), Paris, Not set

University Hospital of Alexandroupolis ( Site 0903), Alexandroupolis, Anatoliki Makedonia Kai Thraki

Evangelismos General Hospital of Athens ( Site 0900), Athens, Attiki

Regional General Hospital of Athens "Laiko" ( Site 0901), Athens, Attiki

MEDI-K ( Site 2602), Guatemala, Not set

Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601), Guatemala, Not set

CELAN,S.A ( Site 2603), Guatemala, Not set

Queen Mary Hospital ( Site 3100), Hong Kong, Not set

Princess Margaret Hospital ( Site 3101), Hong Kong, Not set

Emek Medical Center-Hematology Unit ( Site 1102), Afula, Not set

Carmel Hospital ( Site 1103), Haifa, Not set

Hadassah Medical Center ( Site 1100), Jerusalem, Not set

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203), Rozzano, Milano

IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200), Bologna, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202), Napoli, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204), Roma, Not set

Seoul National University Hospital-Oncology ( Site 0302), Seoul, Not set

Samsung Medical Center ( Site 0300), Seoul, Not set

Health Pharma Professional Research S.A. de C.V: ( Site 2700), Ciudad de Mexico, Distrito Federal

Medivest Centro de Investigación Integral ( Site 2704), Chihuahua, Not set

Centro de Infusion Superare ( Site 2701), Mexico City, Not set

Aotearoa Clinical Trials ( Site 0501), Auckland, Not set

Clínicas AUNA Sede Chiclayo ( Site 2803), Chiclayo, Lambayeque

Clínica San Felipe ( Site 2805), Lima, Not set

Hospital Nacional Edgardo Rebagliati Martins ( Site 2802), Lima, Not set

Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 1305), Walbrzych, Dolnoslaskie

Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site 1301), Wroclaw, Dolnoslaskie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1303), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1300), Warszawa, Mazowieckie

Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302), Gdynia, Pomorskie

Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309), Słupsk, Pomorskie

Pratia Onkologia Katowice ( Site 1306), Katowice, Slaskie

Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400), Bangkok, Krung Thep Maha Nakhon

Chulalongkorn University ( Site 0402), Pathumwan, Krung Thep Maha Nakhon

Maharaj Nakorn Chiang Mai Hospital ( Site 0401), Chiang Mai, Not set

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1912), Yenimahalle, Ankara

Ege University Medicine of Faculty ( Site 1902), Bornova, Izmir

Ankara University Hospital Cebeci-hematology ( Site 1901), Ankara, Not set

Mega Medipol-Hematology ( Site 1909), Istanbul, Not set

Dokuz Eylül Üniversitesi-Hematology ( Site 1905), Izmir, Not set

Ondokuz Mayıs Universitesi ( Site 1907), Samsun, Not set

MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2000), Cherkasy, Cherkaska Oblast

Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2004), Ivano-Frankivsk, Ivano-Frankivska Oblast

Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002), Lviv, Lvivska Oblast

State non-profit enterprise National Cancer Institute ( Site 2001), Kyiv, Not set

National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine ( Site 2005), Kyiv, Not set

Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2003), Kyiv, Not set

Aberdeen Royal Infirmary ( Site 2104), Aberdeen, Aberdeen City

The Royal Cornwall Hospital ( Site 2103), Truro, England

University College London Hospital-Cancer Clinical Trials Unit ( Site 2100), London-Camden, London, City Of

Conditions: DLBCL, Diffuse Large B-Cell Lymphoma

Learn More ›

Magnetic Gastro-Ileal or Gastro-Jejunal Diversion Study ("MGI/MGJ Study")

NCT06073457

Recruiting

The purpose of this clinical research study is to evaluate the feasibility of the GT Metabolic Solutions Magnet System, GJ Biofragmentable ("MagGJ System") for creation of a side-to-side anastomosis for gastro-ileal or gastro-jejunal diversion in obese adults.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/18/2025

Locations: Westmount Surgical Center, Westmount, Quebec +2 locations

Conditions: Obesity, Type 2 Diabetes

Learn More ›

Improving Patient Mental Health With Psychotherapist Virtual Training

NCT07087730

Recruiting

Several types of psychotherapy are equally effective to treat mental disorders. However, many patients remain symptomatic after treatment. The investigators demonstrated that a professional development training program to improve psychotherapists' skills at identifying and repairing therapeutic alliance tensions resulted in improved therapeutic alliance (an important therapeutic ingredient) and patient mental health outcomes. However, the investigators delivered this training program by conventional in-person workshops which limited access by psychotherapists living outside large urban centres. Further, post-study interviews with therapists suggested that cultural/diversity factors complicated the therapeutic alliance. In the current study, the investigators will test the effectiveness and acceptability of a virtually-delivered training program to psychotherapists in North America to improve their capacity to identify and repair problems in the therapeutic alliance, including tensions related to patient diversity. The investigators will also examine how acceptable the virtually-delivered training is to psychotherapists and whether they would use such training in their practice. Participants in the study will be community-based licensed psychotherapists and their patients engaging in therapy in North America. Patient mental health outcomes, therapeutic alliance, and diversity issues will be assessed by comparing outcome measures between three groups: 1) therapists complete a self-paced virtual course + consultation, 2) therapists complete synchronous workshop + consultation, 3) control: therapists do not complete training. The team of investigators developed Canada's largest psychotherapy practice-research network and has expertise in clinical trials, diversity, and education research of virtual training. State of the art training is often out of the reach of therapists who live outside of urban centres, and the effectiveness and acceptability of providing training virtually is not well-studied in mental health care. This study will improve psychotherapists' effectiveness at managing the therapeutic alliance and issues related to diversity, and will improve patient mental health outcomes thus promising to reduce the burden of mental illness. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/18/2025

Locations: University of Ottawa, Ottawa, Ontario

Conditions: Mental Disorders

Learn More ›

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT06726148

Recruiting

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

07/18/2025

Locations: Florida Cancer Specialists, Fort Myers, Florida +11 locations

Conditions: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors

Learn More ›

PulseSelect™ PFA Global Registry

NCT06393920

Recruiting

The PulseSelect™ PFA Global Registry is a prospective, global, multi-center, observational post-approval study. Subjects will be treated with the PulseSelect™ PFA System and followed according to SOC.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: Vancouver General Hospital, Vancouver, British Columbia +14 locations

Conditions: Atrial Fibrillation

Learn More ›

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06603077

Recruiting

The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: Clinical Site 1022, Scottsdale, Arizona +71 locations

Clinical Site 1022, Scottsdale, Arizona

Clinical Site 1026, Tucson, Arizona

Clinical Site 1032, Northridge, California

Clinical Site 1019, Pomona, California

Clinical Site 1009, Sacramento, California

Clinical Site 1011, Washington, District of Columbia

Clinical Site 1029, Boca Raton, Florida

Clinical Site 1002, Coral Gables, Florida

Clinical Site 1015, Maitland, Florida

Clinical Site 1027, North Miami Beach, Florida

Clinical Site 1013, Tampa, Florida

Clinical Site 1008, Savannah, Georgia

Clinical Site 1014, Chicago, Illinois

Clinical Site 1028, West Lafayette, Indiana

Clinical Site 1031, Bowling Green, Kentucky

Clinical Site 1024, Murray, Kentucky

Clinical Site 1001, Boston, Massachusetts

Clinical Site 1007, Ft. Gratiot, Michigan

Clinical Site 1041, Oakland, Michigan

Clinical Site 1003, Portsmouth, New Hampshire

Clinical Site 1023, Bronx, New York

Clinical Site 1036, Brooklyn, New York

Clinical Site 1016, New York, New York

Clinical Site 1020, Cincinnati, Ohio

Clinical Site 1010, Cleveland, Ohio

Clinical Site 1017, Dublin, Ohio

Clinical Site 1004, Philadelphia, Pennsylvania

Clinical Site 1018, Johnston, Rhode Island

Clinical Site 1005, Greenville, South Carolina

Clinical Site 1012, Arlington, Texas

Clinical Site 1203, Darlinghurst, New South Wales

Clinical Site 1201, Westmead, New South Wales

Clinical Site 1202, Carlton, Victoria

Clinical Site 1303, Sofia, Sofia-Grad

Clinical Site 1302, Lovech, Not set

Clinical Site 1301, Pleven, Not set

Clinical Site 1304, Stara Zagora, Not set

Clinical Site 1105, Edmonton, Alberta

Clinical Site 1108, Edmonton, Alberta

Clinical Site 1103, Barrie, Ontario

Clinical Site 1104, Hamilton, Ontario

Clinical Site 1107, London, Ontario

Clinical Site 1106, Toronto, Ontario

Clinical Site 1101, Saskatoon, Saskatchewan

Clinical Site 1401, Praha 10, Prague

Clinical Site 1402, Praha 5, Prague

Clinical Site 1503, Antony, Hauts-de-Seine

Clinical Site 1504, Paris, Ile-de-France

Clinical Site 1505, Amiens, Picardie

Clinical Site 1502, Lyon, Rhône

Clinical Site 1501, Rouen Cedex, Seine-Maritime

Clinical Site 1606, Erlangen, Bayern

Clinical Site 1604, Frankfurt, Hessen

Clinical Site 1601, Bochum, Nordrhein-Westfalen

Clinical Site 1602, Muenster, Nordrhein-Westfalen

Clinical Site 1901, Torrette, Ancona

Clinical Site 1903, Rozzano, Milano

Clinical Site 1908, Milano, Not set

Clinical Site 1907, Roma, Not set

Clinical Site 1904, Roma, Not set

Clinical Site 1702, Wroclaw, Kujawsko-Pomorskie

Clinical Site 1703, Bialystok, Podlaskie

Clinical Site 1701, Warszawa, Pomorskie

Clinical Site 1705, Warszawa, Pomorskie

Clinical Site 1704, Ossy, Slaskie

Clinical Site 2202, Svidnik, Presovsky Kraj

Clinical Site 2201, Trnava, Trnavsky kraj

Clinical Site 1801, Manises, Valencia

Clinical Site 1802, Granada, Not set

Clinical Site 1803, Madrid, Not set

Clinical Site 1804, Sevilla, Not set

Clinical Site 2001, Gaziantep, Not set

Conditions: Hidradenitis Suppurativa

Learn More ›

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515

Recruiting

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: City of Hope, Duarte, California +51 locations

City of Hope, Duarte, California

University of California, Los Angeles (UCLA), Los Angeles, California

Sarah Cannon Research Institute at HealthOne, Denver, Colorado

Sibley Memorial Hospital, Washington, District of Columbia

Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando, Florida

Emory University School of Medicine, Atlanta, Georgia

Community Health Network, Indianapolis, Indiana

Massachusetts General Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan

New York University (NYU) Langone Medical Center, New York, New York

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York

Duke University Medical Center, Durham, North Carolina

University of Cincinnati (UC) - Cancer Institute, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh, Pennsylvania

Sarah Cannon Research Institute, Nashville, Tennessee

USO - US Oncology Research Network, Nashville, Tennessee

Vanderbilt University School of Medicine, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

South Texas Accelerated Research Therapeutics (START), San Antonio, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

Fred Hutchinson Cancer Center, Seattle, Washington

University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin

The Ottawa Hospital, Ottawa, Ontario

Princess Margaret Hospital, Toronto, Ontario

Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Not set

Beijing Cancer hospital, Beijing, Not set

Harbin Medical University Cancer Hospita, Harbin, Not set

Fudan University Cancer Center, Shanghai, Not set

Centre Leon Berard, Lyon, Not set

Centre d'Essais Precoces en Cancerologie de Marseille (CEPCM) - AP-HM Hopital de La Timone, Marseille, Not set

Oncopole Claudius Regaud, Toulouse, Not set

Institut Gustave Roussy, Villejuif cedex, Not set

Charite Universitaetsmedizin Berlin, Berlin, Not set

Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Not set

Universitaetsklinikum Essen, Essen, Not set

Klinikum der Ludwig-Maximilians-Universitaet Muenchen, Munchen, Not set

START Dublin Early Phase Clinical Trials Unit, Dublin, Not set

Azienda Ospedaliera Universitaria - Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Not set

UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma, Not set

Centro Ricerche Cliniche di Verona s.r.l., Verona, Not set

Kanagawa cancer center, Kanagawa, Not set

National Cancer Center Hospital East, Kashiwa, Chiba, Not set

Aichi Cancer Center Hospital, Nagoya, Not set

Kansai Medical University Hospital, Osaka, Not set

National Cancer Center Hospital, Tokyo, Not set

South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos, Barcelona, Not set

Hospital Universitario Vall d'Hebron, Barcelona, Not set

South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

Learn More ›

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NCT05379595

Recruiting

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC) (Ph2 cohorts), and to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: O Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama +52 locations

O Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama

University of Southern California, Los Angeles, California

University of California, Los Angeles UCLA, Los Angeles, California

Georgetown University Hospital, Washington, District of Columbia

H Lee Moffitt Cancer Center, Tampa, Florida

University of Maryland School of Medicine, Baltimore, Maryland

University of Michigan Health System, Ann Arbor, Michigan

Start Midwest, Grand Rapids, Michigan

Hattiesburg Clinic, Hattiesburg, Mississippi

NYU Langone Long Island Clinical Research Associates, New York, New York

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York, New York

Stephenson Cancer Center, Oklahoma City, Oklahoma

Vanderbilt Ingram Cancer Center, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

Institut Jules Bordet, Anderlecht, Not set

Cliniques Universitaires Saint Luc, Bruxelles, Not set

UZ Antwerpen, Edegem, Not set

Universitair Ziekenhuis Gasthuisberg, Leuven, Not set

BC Cancer Agency - Vancouver BC, Vancouver, British Columbia

The Ottawa Hospital Cancer Centre, Ottawa, Ontario

Princess Margaret Cancer Centre University Health Network, Toronto, Ontario

The Second Hospital To Dalian Medical University, Da Lian Shi, Not set

Sun Yat-sen University - The Sixth Affiliated Hospital Guangdong Gastrointestinal Hospital, Guangzhou, Not set

The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, Not set

Hubei province tumor hospital, Wu Han Shi, Not set

Asklepios Klinik Altona, Hamburg, Not set

Ludwig-Maximilians-Universitaet Muenchen, Munich, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Not set

A O Ospedale Niguarda Ca Granda, Milano, Not set

Azienda Ospedaliero Universitaria Pisana, Pisa, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Not set

University Malaya Medical Centre, Kuala Lumpur, Not set

Hospital Umum Sarawak, Kuching, Not set

Beacon Hospital Sdn Bhd, Petaling Jaya, Not set

Ad Vance Medical Research, Ponce, Not set

Pan American Center for Oncology Trials LLC, Rio Piedras, Not set

Hosp Univ Vall D Hebron, Barcelona, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Univ. Ramon Y Cajal, Madrid, Not set

Hosp Univ Fund Jimenez Diaz, Madrid, Not set

Hosp Univ Hm Sanchinarro, Madrid, Not set

Hosp. Univ. Marques de Valdecilla, Santander, Not set

Hosp. Clinico Univ. de Valencia, Valencia, Not set

Changhua Christian Hospital, Changhua, Not set

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Not set

Chi Mei Medical Center Liu Ying, Liou Ying Township, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Linkou Chang Gung Memorial Hospital, Taoyuan, Not set

Conditions: Advanced or Metastatic Colorectal Cancer

Learn More ›

Stimulating Postural Control to Augment Rehabilitation After Cerebral Stroke (SPARC): a Pilot Trial

NCT06987682

Recruiting

People living with stroke have a high risk of falling and this risk increases as mobility improves over the first year post-stroke. Despite the high number of falls, there is a lack of interventions to prevent falls after stroke. One possible solution is to alter nerve activity through delivery of a stimulus, such as electrical stimulation. The purpose of this study is to test the study plan and to find out whether enough participants will join a larger study and accept the study procedures of c... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: KITE Research Institute, Toronto Rehabilitation Institute - University Health Network, Toronto, Ontario

Conditions: Stroke

Learn More ›

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226

Recruiting

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Gender:

ALL

Ages:

12 years and above

Trial Updated:

07/17/2025

Locations: Cahaba Research Inc, Birmingham, Alabama +159 locations

Cahaba Research Inc, Birmingham, Alabama

California Dermatology & Clinical Research Institute, Encinitas, California

T Joseph Raoof Md Inc, Encino, California

First OC Dermatology, Fountain Valley, California

Dermatologist Medical Group of North County, Inc., Oceanside, California

NorCal Clinical Research, Rocklin, California

Integrative Skin Science and Research, Sacramento, California

MedDerm Associates, San Diego, California

Southern California Dermatology, Santa Ana, California

Olive View-UCLA Education & Research Institute, Sylmar, California

University of Conn Health Center, Farmington, Connecticut

Driven Research LLC, Coral Gables, Florida

Bioclinical Research Alliance Inc., Miami, Florida

Renstar Medical Research, Ocala, Florida

Forcare Clinical Research Inc, Tampa, Florida

Hamilton Research LLC, Alpharetta, Georgia

Northshore Medical Group, Skokie, Illinois

Indiana Clinical Trial Center, Plainfield, Indiana

University of Iowa, Iowa City, Iowa

Equity Medical, Bowling Green, Kentucky

Tufts Medical Center, Boston, Massachusetts

Metro Boston Clinical Partners, Brighton, Massachusetts

The Derm Institute of West Michigan, Caledonia, Michigan

Henry Ford Hospital, Detroit, Michigan

Hamzavi Dermatology, Fort Gratiot, Michigan

Somerset Skin Centre, Troy, Michigan

Minnesota Clinical Study Center, New Brighton, Minnesota

Cleaver Dermatology, Kirksville, Missouri

MediSearch Clinical Trials, Saint Joseph, Missouri

Mount Sinai Doctors Dermatology, New York, New York

Sadick Research Group, New York, New York

Wilmington Dermatology Center, Wilmington, North Carolina

Optima Research, Boardman, Ohio

Apex Dermatology Mayfield Heights, Mayfield Heights, Ohio

Oregon Medical Research Center, Portland, Oregon

Oregon Dermatology and Research Center, Portland, Oregon

Clinical Research Philadelphia, Philadelphia, Pennsylvania

UPMC Department of Dermatology, Pittsburgh, Pennsylvania

Health Concepts, Rapid City, South Dakota

Advanced Research Experts PLLC, Nashville, Tennessee

Arlington Research Center, Inc., Arlington, Texas

Modern Research Associates PLLC, Dallas, Texas

Center for Clinical Studies, Houston, Texas

Progressive Clinical Research, San Antonio, Texas

Texas Dermatology and Laser Specialists, San Antonio, Texas

Center for Clinical Studies, Webster, Texas

Kalo Clinical Research, West Valley City, Utah

Frontier Derm Partners CRO, LLC, Mill Creek, Washington

Consultora Integral de Salud SRL, Barrio Gral Paz Cba Capital, Not set

Instituto Medico De Alta Complejidad (IMAC), Buenos Aires, Not set

Mindout Research, Buenos Aires, Not set

Instituto de Neumonologia y Dermatologia, Buenos Aires, Not set

Buenos Aires Skin, Caba, Not set

Investigaciones Medicas IMOBA SRL, Caba, Not set

CIPREC, Caba, Not set

Halitus Instituto Medico S.A. - Dermatologia y Estetica, Caba, Not set

Mautalen Salud e Investigacion, Caba, Not set

Hospital Italiano de Buenos Aires, Caba, Not set

Instituto De Especialidades De La Salud SRL, Rosario, Not set

MR Medicina Reumatologica, San Fernando, Not set

Instituto de Investigaciones Medicas Tucuman, Tucuman, Not set

Monash Medical Centre, Clayton, Not set

Cornerstone Dermatology, Coorparoo, Not set

Premier Specialists, Kogarah, Not set

The Alfred Hospital, Melbourne, Not set

Royal Melbourne Hospital, Melbourne, Not set

ISHI dermatology, Mitcham, Not set

Westmead Hospital, Westmead, Not set

Veracity Clinical Research, Woolloongabba, Not set

LKH Feldkirch, Feldkirch, Not set

Kepler Universitatsklinikum GmbH, Linz, Not set

Universtitatsklinikum St Polten, Sankt Polten, Not set

Allgemeines Krankenhaus der Stadt Wien, Wien, Not set

UZ Brussel, Brussel, Not set

AZ St. Lucas, Gent, Not set

Ghent University Hospital, Ghent, Not set

Universitair Ziekenhuis Leuven, Leuven, Not set

Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Not set

Dermatologie Maldegem, Maldegem, Not set

Skincare Studio Inc Dermatology Clinical Trials, St Johns, Newfoundland and Labrador

CCA Medical Research Corporation, Ajax, Ontario

SimcoDerm Medical and Surgical Dermatology Centre, Barrie, Ontario

Dermatrials Research, Hamilton, Ontario

Lovegrove Dermatology, London, Ontario

Lynderm Research Inc., Markham, Ontario

Alliance Clinical Trials, Waterloo, Ontario

Innovaderm Research Inc., Montreal, Quebec

The Centre de recherche Saint-Louis, Quebec, Not set

Aalborg Sygehus Syd, Aalborg, Not set

Aarhus University Hospital, Aarhus, Not set

Gentofte Hospital, Hellerup, Not set

Bispebjerg Hospital, Kobenhavn NV, Not set

Odense University Hospital, Odense, Not set

Sjællands University hospital, Roskilde, Not set

Klinikum Augsburg, Augsburg, Not set

Fachklinik Bad Bentheim, Bad Bentheim, Not set

ISA - Interdisciplinary Study Association GmbH, Berlin, Not set

Universitatsklinikum Bonn, Bonn, Not set

Studienzentrum an der Hase GbR, Bramsche, Not set

Rosenpark Research GmbH, Darmstadt, Not set

Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden, Dresden, Not set

Derma-Study-Center Friedrichshafen GmbH, Friedrichshafen, Not set

Universitaetsklinikum Schleswig Holstein Campus Kiel, Kiel, Not set

Studienzentrum Dr Schwarz Germany, Langenau, Not set

Dermatologie Mahlow, Mahlow, Not set

Gemeinschaftspraxis Dres. Quist, Mainz, Not set

Universitaetsklinikum Muenster, Muenster, Not set

Hautarztpraxis, Witten, Not set

Obudai Egeszsegugyi Centrum Kft, Budapest, Not set

Uno Medical Trials Ltd., Budapest, Not set

Derma-B Kft, Debrecen, Not set

Debreceni Egyetem Klinikai Kozpont, Debrecen, Not set

Gyongyosi Bugat Pal Korhaz, Gyongyos, Not set

Synexus Magyarorszag Kft, Gyula, Not set

Porcika Klinika - Vasarhelyi Sarkanyfu Kft., Hodmezovasarhely, Not set

Somogy Varmegyei Kaposi Mor Oktato Korhaz, Kaposvar, Not set

Bacs-kiskun Megyei Korhaz, Kecskemet, Not set

Allergo-Derm Bakos Kft., Szolnok, Not set

Medmare Egeszsegugyi Es Szolgaltato Bt., Veszprem, Not set

Osteo-Medic s.c A. Racewicz, J Supronik, Bialystok, Not set

Specderm Poznanska sp j, Bialystok, Not set

Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska, Elblag, Not set

Care Clinic Sp z o o, Katowice, Not set

Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna, Krakow, Not set

Dermed Centrum Medyczne Sp z o o, Lodz, Not set

Etyka Osrodek Badan Klinicznych Tomasz Pesta S K A, Olsztyn, Not set

SOLUMED Centrum Medyczne, Poznan, Not set

Velocity Skierniewice sp z o o, Skierniewice, Not set

Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej, Warszawa, Not set

Klinika Ambroziak Dermatologia, Warszawa, Not set

WroMedica, Wroclaw, Not set

Centrum Medyczne Oporow, Wroclaw, Not set

Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes, Braga, Not set

Unidade Local De Saude Da Regiao De Leiria Epe, Leiria, Not set

Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos, Lisboa, Not set

Hosp. Cuf Descobertas, Lisboa, Not set

Ulssa Hosp. Santo Antonio, Porto, Not set

Hosp. Gral. Univ. Dr. Balmis, Alicante, Not set

Hosp. Univ. de Cruces, Barakaldo, Not set

Hosp. Clinic de Barcelona, Barcelona, Not set

Hosp. Univ. San Cecilio, Granada, Not set

Grupo Dermatologico Y Estetico Pedro Jaen, Madrid, Not set

Hosp. Univ. de La Princesa, Madrid, Not set

Hosp. Univ. 12 de Octubre, Madrid, Not set

Hosp. de Manises, Manises, Not set

Hosp. Clinico Univ. de Santiago, Santiago Compostela, Not set

Hosp. Virgen Macarena, Sevilla, Not set

Hosp. Ntra. Sra. de Valme, Sevilla, Not set

Hosp. Univ. I Politecni La Fe, Valencia, Not set

Hosp. de La Marina Baixa, Villajoyosa, Not set

Hosp. Clinico Univ. Lozano Blesa, Zaragoza, Not set

Hosp. Univ. Miguel Servet, Zaragoza, Not set

Dudley Group NHS Foundation Trust, Dudley, Not set

London North West University Healthcare NHS Trust, Harrow, Not set

The Queen Elizabeth Hospital NHS Foundation Trust, Kings Lynn, Not set

Guys and St Thomas NHS Foundation Trust, London, Not set

Royal Berkshire Hospital, Reading, Not set

Salford Royal Hospital, Salford, Not set

University Hospital Southampton, Southampton, Not set

Mid Yorkshire NHS Trust, Wakefield, Not set

Conditions: Plaque Psoriasis

Learn More ›

Feasibility and Acceptability of an Evidence-Informed Virtual Intervention to Reduce Perceptions of Injustice Following Work Injury

NCT07072702

Recruiting

Many individuals who have sustained disabling injuries in the workplace react to their situation with a sense of 'injustice'. Research over the past 20 years has revealed that, interpreting one's post-injury life situation as 'unjust', actually interferes with recovery from the disabling injury. Post-injury perceptions of injustice contribute to more severe pain, more severe symptoms of depression and PTSD, and more prolonged absence from work. Several clinical researchers have highlighted the need to develop approaches to treatment that can reduce post-injury perceptions of injustice. A brief intervention was developed to reduce post-injury perceptions of injustice. The intervention consists of 4 30-minute sessions with a psychologist. The intervention is called 'Managing Post-Injury Challenges' (MPIC). The MPIC sessions are delivered virtually (online). As a first step toward determining whether MPIC has added value for promoting more successful recovery following work injury, the proposed research will assess the feasibility of MPIC. Some of the feasibility questions that will be addressed include: Are injured workers interested in participating in MPIC? Do injured individuals remain sufficiently engaged to complete all 4 sessions of MPIC? Does participation in MPIC contribute to meaningful reductions in perceived injustice? And are injured individuals satisfied with the benefits of MPIC? MPIC differs from many other rehabilitation interventions in that it focuses on a 'risk-factor' for problematic recovery as opposed to treating a specific health or mental health problem. At this time, there is little information about whether injured workers are interested in interventions focusing on 'risk factors' for problematic recovery. As a first step in evaluating the effectiveness of MPIC, it is necessary to demonstrate that MPIC is acceptable to injured workers. We would consider the study to be successful if 1) at least 75% of eligible injured workers agree to enrol in MPIC, 2) if at least 75% of participants attend all 4 sessions of MPIC, and if at least 75% of participants are satisfied with the benefits they derived from their involvement in MPIC. If MPIC is ultimately shown to be effective in reducing post-injury perceptions of injustice, offering MPIC to injured workers with elevated scores on a measure of perceived injustice could contribute to more successful recovery. Read Less

Gender:

ALL

Ages:

Between 25 years and 65 years

Trial Updated:

07/17/2025

Locations: McGill University, Montreal, Quebec

Conditions: MSK Conditions

Learn More ›